Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
Canada
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Citrate, Toremifene
2. Fareston
3. Fc 1157a
4. Fc-1157a
5. Fc1157a
6. Toremifene
7. Toremifene Citrate (1:1)
8. Toremifene, (e)-isomer
1. 89778-27-8
2. Fareston
3. Toremifene Citrate [usan]
4. Toremifene (citrate)
5. Fc 1157a
6. Nk 622
7. Nsc 613680
8. Fc-1157a
9. 89778-27-8 (citrate)
10. Nsc-613680
11. Nsc613680
12. 2-(p-((z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethylethylamine Citrate (1:1)
13. 2498y783qt
14. Toremifene Citrate (fareston, Acapodene)
15. Dsstox_cid_1367
16. Dsstox_rid_76113
17. Dsstox_gsid_21367
18. (z)-2-(4-(4-chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-n,n-dimethylethan-1-amine 2-hydroxypropane-1,2,3-tricarboxylate
19. Ethanamine, 2-(4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethyl-, (z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
20. (2-{4-[(1z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine; 2-hydroxypropane-1,2,3-tricarboxylic Acid
21. 2-({4-[(1z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-n,n-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate (salt)
22. Cas-89778-27-8
23. Ccris 6719
24. Unii-2498y783qt
25. 2-[p-[(z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-n,n-dimethylethylamine Citrate (1:1)
26. Cpd000469213
27. Schembl4564
28. (z)-4-chloro-1,2-diphenyl-1-(4-(2-(n,n-dimethylamino)ethoxy)phenyl)-1-butene Citrate (1:1)
29. Mls001306432
30. Mls006011608
31. Chebi:9636
32. Toremifene Citrate [mi]
33. Chembl1200675
34. Dtxsid2021367
35. Toremifene Citrate (jan/usan)
36. Toremifene Citrate [jan]
37. Hms2052c03
38. Hms2230p09
39. Hms3264l11
40. Pharmakon1600-01505682
41. Toremifene Citrate [vandf]
42. Toremifene Citrate [mart.]
43. Hy-b0005
44. Toremifene Citrate [who-dd]
45. Tox21_111877
46. Tox21_301740
47. Mfcd01729016
48. Nsc759190
49. S1776
50. Akos015888270
51. Ac-1985
52. Ccg-101072
53. Cs-1272
54. Ks-5242
55. Nc00322
56. Nsc-759190
57. 2-[4-[(z)-4-chloro-1,2-diphenyl-but-1-enyl]phenoxy]-n,n-dimethyl-ethanamine; Citric Acid
58. Toremifene Citrate [orange Book]
59. Ncgc00255310-01
60. 2-[4-[(z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-n,n-dimethylethanamine; 2-hydroxypropane-1,2,3-tricarboxylic Acid
61. Smr004703372
62. Toremifene Citrate Salt, >=98% (hplc)
63. Sw197702-3
64. T2832
65. D00967
66. 778t267
67. A843307
68. Sr-01000763502-3
69. Q27253831
70. 2-[p-[(z)-4-chloro-1,n- Dimethylethylamine Citrate (1:1)
71. (z)-2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-n,n-dimethylethanamine Citrate
72. (z)-2-[4-(4-chloro-1,n- Dimethylethanamine, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
73. (z)-4-chloro-1-(4-dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene Citrate
74. (z)-2-(4-(4-chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-n,n-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate
75. (z)-2-(4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy)-n,n-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate
76. 2-[4-[(z)-4-chloranyl-1,2-diphenyl-but-1-enyl]phenoxy]-n,n-dimethyl-ethanamine; 2-oxidanylpropane-1,2,3-tricarboxylic Acid
Molecular Weight | 598.1 g/mol |
---|---|
Molecular Formula | C32H36ClNO8 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 14 |
Exact Mass | 597.2129448 g/mol |
Monoisotopic Mass | 597.2129448 g/mol |
Topological Polar Surface Area | 145 Ų |
Heavy Atom Count | 42 |
Formal Charge | 0 |
Complexity | 710 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.
Fareston is not recommended for patients with estrogen receptor negative tumours.
Antineoplastic Agents, Hormonal
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
Selective Estrogen Receptor Modulators
A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63) (See all compounds classified as Selective Estrogen Receptor Modulators.)
L02BA02
Related Excipient Companies
Excipients by Applications
Global Sales Information
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
81
PharmaCompass offers a list of Toremifene Citrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Toremifene Citrate manufacturer or Toremifene Citrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Toremifene Citrate manufacturer or Toremifene Citrate supplier.
PharmaCompass also assists you with knowing the Toremifene Citrate API Price utilized in the formulation of products. Toremifene Citrate API Price is not always fixed or binding as the Toremifene Citrate Price is obtained through a variety of data sources. The Toremifene Citrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Toremifene Citrate, Fareston, Acapodene manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Toremifene Citrate, Fareston, Acapodene, including repackagers and relabelers. The FDA regulates Toremifene Citrate, Fareston, Acapodene manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Toremifene Citrate, Fareston, Acapodene API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Toremifene Citrate, Fareston, Acapodene manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Toremifene Citrate, Fareston, Acapodene supplier is an individual or a company that provides Toremifene Citrate, Fareston, Acapodene active pharmaceutical ingredient (API) or Toremifene Citrate, Fareston, Acapodene finished formulations upon request. The Toremifene Citrate, Fareston, Acapodene suppliers may include Toremifene Citrate, Fareston, Acapodene API manufacturers, exporters, distributors and traders.
click here to find a list of Toremifene Citrate, Fareston, Acapodene suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Toremifene Citrate, Fareston, Acapodene DMF (Drug Master File) is a document detailing the whole manufacturing process of Toremifene Citrate, Fareston, Acapodene active pharmaceutical ingredient (API) in detail. Different forms of Toremifene Citrate, Fareston, Acapodene DMFs exist exist since differing nations have different regulations, such as Toremifene Citrate, Fareston, Acapodene USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Toremifene Citrate, Fareston, Acapodene DMF submitted to regulatory agencies in the US is known as a USDMF. Toremifene Citrate, Fareston, Acapodene USDMF includes data on Toremifene Citrate, Fareston, Acapodene's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Toremifene Citrate, Fareston, Acapodene USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Toremifene Citrate, Fareston, Acapodene suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Toremifene Citrate, Fareston, Acapodene Drug Master File in Japan (Toremifene Citrate, Fareston, Acapodene JDMF) empowers Toremifene Citrate, Fareston, Acapodene API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Toremifene Citrate, Fareston, Acapodene JDMF during the approval evaluation for pharmaceutical products. At the time of Toremifene Citrate, Fareston, Acapodene JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Toremifene Citrate, Fareston, Acapodene suppliers with JDMF on PharmaCompass.
A Toremifene Citrate, Fareston, Acapodene written confirmation (Toremifene Citrate, Fareston, Acapodene WC) is an official document issued by a regulatory agency to a Toremifene Citrate, Fareston, Acapodene manufacturer, verifying that the manufacturing facility of a Toremifene Citrate, Fareston, Acapodene active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Toremifene Citrate, Fareston, Acapodene APIs or Toremifene Citrate, Fareston, Acapodene finished pharmaceutical products to another nation, regulatory agencies frequently require a Toremifene Citrate, Fareston, Acapodene WC (written confirmation) as part of the regulatory process.
click here to find a list of Toremifene Citrate, Fareston, Acapodene suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Toremifene Citrate, Fareston, Acapodene as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Toremifene Citrate, Fareston, Acapodene API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Toremifene Citrate, Fareston, Acapodene as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Toremifene Citrate, Fareston, Acapodene and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Toremifene Citrate, Fareston, Acapodene NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Toremifene Citrate, Fareston, Acapodene suppliers with NDC on PharmaCompass.
Toremifene Citrate, Fareston, Acapodene Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Toremifene Citrate, Fareston, Acapodene GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Toremifene Citrate, Fareston, Acapodene GMP manufacturer or Toremifene Citrate, Fareston, Acapodene GMP API supplier for your needs.
A Toremifene Citrate, Fareston, Acapodene CoA (Certificate of Analysis) is a formal document that attests to Toremifene Citrate, Fareston, Acapodene's compliance with Toremifene Citrate, Fareston, Acapodene specifications and serves as a tool for batch-level quality control.
Toremifene Citrate, Fareston, Acapodene CoA mostly includes findings from lab analyses of a specific batch. For each Toremifene Citrate, Fareston, Acapodene CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Toremifene Citrate, Fareston, Acapodene may be tested according to a variety of international standards, such as European Pharmacopoeia (Toremifene Citrate, Fareston, Acapodene EP), Toremifene Citrate, Fareston, Acapodene JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Toremifene Citrate, Fareston, Acapodene USP).